"We remain on track for the opening of phase 2 in the next few months. We also expect to see the full phase 1 results presented at a scientific meeting in 2025," says David E. Gauden, DPhil.

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter. "When determining which code you should use, you must consider your ...

"Overall, TAR-200 is being tested with the aim of changing the therapeutic paradigm of patients with an early bladder cancer diagnosis, including non–muscle-invasive disease and muscle-invasive ...

F-flotufolastat shows a 69% detection rate for recurrent prostate cancer in patients with PSA levels above 0.2 ng/mL post-prostatectomy. The agent demonstrates a 50% detection rate for PSAs below 0.2 ...

A 4-gene signature (ATM, RB1, FANCC, ERCC2) correlates with tumor absence post-neoadjuvant chemotherapy in muscle-invasive bladder cancer. The biomarker is more effective at predicting disease ...

Aquablation offers personalized treatment plans using real-time ultrasound and AI, distinguishing it from traditional TURP procedures. The heat-free nature of Aquablation reduces post-operative ...

"Donor-advised funds are a fast-growing charitable giving vehicle in the US because they are one of the easiest and most tax-advantageous ways to give to charity," writes Jeff Witz, CFP. “[This way, I ...

"We wanted to look at the importance of genetic testing in patients with GU cancer and the impact that it has on their treatment decision-making, and the pathways that we put them on," says Mouneeb ...

Aquablation with HYDROS is a transurethral water jet procedure for BPH, combining resective and non-resective therapy benefits. The HYDROS system uses AI-powered treatment planning and real-time ...

“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade.